NeuroSearch
NeuroSearch was a Scandinavian biopharmaceutical company focused on developing novel pharmaceutical agents for central nervous system disorders. The company utilized a well-established drug discovery platform centered on ion channels and partnered with major pharmaceutical firms such as Eli Lilly, Janssen Pharmaceutica, and GlaxoSmithKline for financing and collaboration on its projects. NeuroSearch maintained a diverse portfolio of preclinical drug candidates and held equity interests in several biotechnology firms. With around 220 employees, its operations were based in Ballerup, Denmark, and Gothenburg, Sweden. In 2019, NeuroSearch was acquired by NTG Nordic Transport Group A/S, a company specializing in transportation services across Europe and internationally.
The Carlson Research Group is a management consulting firm that offers recruitment and research solutions.
Atonomics A/S is a technology company based in Copenhagen, Denmark, established in 2000. It specializes in designing and manufacturing the Atolyzer platform, which facilitates testing and monitoring in various healthcare settings, including pharmacies, clinics, and hospitals. Atonomics offers the Trace system, a personal biomarker device that enables users to measure critical health markers related to lifestyle and chronic diseases. This device allows for the assessment of lipid profiles, blood percentage, and blood sugar levels, catering to the needs of diabetic patients and individuals managing health conditions. With a focus on simplicity and usability, Trace is designed for easy integration with smartphones, enabling users to track their health data conveniently and affordably.
NsGene A/S is a Danish biotechnology company dedicated to developing biological products aimed at treating neurological diseases. Based in Ballerup, Denmark, with a location in Providence, Rhode Island, the company specializes in identifying neurotrophic proteins that have therapeutic effects on the nervous system. It focuses on creating technologies to deliver protein therapeutics across the blood-brain barrier and into diseased nerve cells. Among its notable products are NSG0202, which is designed for brain repair in Alzheimer's patients, and Neublastin, a therapeutic protein intended for alleviating neuropathic pain. NsGene targets several conditions with significant unmet medical needs, including Alzheimer’s disease, Parkinson's disease, deafness, epilepsy, cortico-basal degeneration, and Huntington’s disease. Founded in 1999, the company is situated in the Medicon Valley region, a hub for life sciences innovation.
Azign Bioscience A/S develops technologies to determine gene expression, which can rationally identify genes that are affected significantly, for instance in the course of a specific disease or during treatment.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.